ERGO.US Entia Biosciences Inc

Healthcare Biotechnology USA Stocks
0.0023 USD
Close of Nov 14, 2026
0.0001 0.0023
Market cap
USD 77.4K
P/E
-
P/B
-
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2022.

Is ERGO.US undervalued?

Graham number

The Graham number of Entia Biosciences Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Entia Biosciences Inc fundamental analysis

No fundamental analysis for Entia Biosciences Inc yet.

Entia Biosciences Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Entia Biosciences Inc

Entia Biosciences, Inc. engages in the development, production, and distribution of dietary supplements, nutraceuticals, and medical food products in the United States. The company develops ErgoD2, a pharmaceutical grade organic compound for the improvement of iron homeostasis and mitigation of iron-related disorders presenting in anemia, chronic kidney disease, and select neurodegenerative diseases. It is also involved in the discovery, scientific evaluation, and marketing …

Full company profile